Jim Simons’s NovoCure NVCR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $16.9M | Buy |
1,551,554
+163,800
| +12% | +$2.05M | 0.03% | 727 |
|
|
2025
Q4 | $17.9M | Buy |
1,387,754
+314,900
| +29% | +$4.04M | 0.03% | 651 |
|
|
2025
Q3 | $13.9M | Sell |
1,072,854
-227,200
| -17% | -$3.04M | 0.02% | 912 |
|
|
2025
Q2 | $23.1M | Buy |
1,300,054
+531,400
| +69% | +$9.26M | 0.03% | 643 |
|
|
2025
Q1 | $13.7M | Buy |
768,654
+34,300
| +5% | +$779K | 0.02% | 843 |
|
|
2024
Q4 | $21.9M | Sell |
734,354
-9,800
| -1% | -$207K | 0.03% | 630 |
|
|
2024
Q3 | $11.6M | Sell |
744,154
-16,021
| -2% | -$290K | 0.02% | 965 |
|
|
2024
Q2 | $13M | Buy |
760,175
+480,600
| +172% | +$8.45M | 0.02% | 784 |
|
|
2024
Q1 | $4.37M | Buy |
279,575
+178,200
| +176% | +$2.62M | 0.01% | 1500 |
|
|
2023
Q4 | $1.51M | Buy |
+101,375
| New | +$1.36M | ﹤0.01% | 2124 |
|
|
2022
Q3 | – | Sell |
-18,386
| Closed | -$1.28M | – | 4305 |
|
|
2022
Q2 | $1.28M | Sell |
18,386
-29,589
| -62% | -$2.23M | ﹤0.01% | 2539 |
|
|
2022
Q1 | $3.98M | Sell |
47,975
-131,116
| -73% | -$9.66M | ﹤0.01% | 1755 |
|
|
2021
Q4 | $13.4M | Sell |
179,091
-34,884
| -16% | -$3.5M | 0.02% | 922 |
|
|
2021
Q3 | $24.9M | Sell |
213,975
-12,800
| -6% | -$1.94M | 0.03% | 577 |
|
|
2021
Q2 | $50.3M | Sell |
226,775
-181,800
| -44% | -$35.4M | 0.06% | 323 |
|
|
2021
Q1 | $54M | Buy |
408,575
+110,605
| +37% | +$17.5M | 0.07% | 322 |
|
|
2020
Q4 | $51.6M | Sell |
297,970
-679,700
| -70% | -$93M | 0.06% | 340 |
|
|
2020
Q3 | $109M | Sell |
977,670
-1,022,900
| -51% | -$81.8M | 0.11% | 184 |
|
|
2020
Q2 | $119M | Sell |
2,000,570
-244,900
| -11% | -$16.1M | 0.1% | 204 |
|
|
2020
Q1 | $151M | Buy |
2,245,470
+3,475
| +0.2% | +$275K | 0.15% | 141 |
|
|
2019
Q4 | $189M | Sell |
2,241,995
-133,775
| -6% | -$10.8M | 0.15% | 144 |
|
|
2019
Q3 | $178M | Buy |
2,375,770
+320,300
| +16% | +$25.6M | 0.15% | 135 |
|
|
2019
Q2 | $130M | Buy |
2,055,470
+199,200
| +11% | +$10.1M | 0.11% | 189 |
|
|
2019
Q1 | $89.4M | Buy |
1,856,270
+785,800
| +73% | +$37.8M | 0.08% | 286 |
|
|
2018
Q4 | $35.8M | Buy |
1,070,470
+231,275
| +28% | +$8.46M | 0.04% | 575 |
|
|
2018
Q3 | $44M | Buy |
839,195
+156,592
| +23% | +$6.23M | 0.05% | 495 |
|
|
2018
Q2 | $21.4M | Buy |
682,603
+501,203
| +276% | +$13.9M | 0.02% | 883 |
|
|
2018
Q1 | $3.96M | Sell |
181,400
-74,875
| -29% | -$1.61M | ﹤0.01% | 1968 |
|
|
2017
Q4 | $5.18M | Buy |
+256,275
| New | +$4.93M | 0.01% | 1785 |
|
Other funds holding NVCR
SCM
VPM
VCM
QCM
Jim Simons's NVCR Position: Q1 2026 in Review
Jim Simons increased its NovoCure (NVCR) stake by 12% in Q1 2026, buying an estimated $2.05M and bringing the position to 1,551,554 shares worth $16.9M. The position accounts for 0.03% of the portfolio, ranked #727.
Jim Simons first reported a position in NVCR in Q4 2017 and has held it in 29 quarters since. The position peaked at $189M in Q4 2019. 223 funds tracked by Wall St. Rank hold NVCR as of Q1 2026.
- Jim Simons held 1,551,554 shares of NovoCure worth $16.9M as of Q1 2026.
- Jim Simons bought 163,800 NovoCure shares in Q1 2026, an estimated $2.05M.
- NovoCure made up 0.03% of Jim Simons's portfolio in Q1 2026, its #727 holding.
- Jim Simons first reported a position in NovoCure in Q4 2017 and has held it in 29 quarters since.
- Jim Simons's NovoCure position peaked at $189M in Q4 2019.
- 223 funds tracked by Wall St. Rank held NovoCure as of Q1 2026.
Based on Renaissance Technologies's 13F filing for Q1 2026, filed 14 May 2026.